HELP YOUR ELIGIBLE PATIENTS SAVE ON BESIVANCE*

Bausch + Lomb Access Program prescription copay offer card

With the Bausch + Lomb Access Program, most eligible commercially insured patients pay no more than $35 co-pay for their BESIVANCE 5 mL bottle prescription and up to 5 refills.*

Patients can download and activate their Bausch + Lomb Access card by visiting bauschaccessprogram.com.

  • Patients who receive a physical co-pay card in office can activate online at blsavings.com, on the phone by calling 1-866-693-4880, or by texting BLSAVINGS to 24109.
  • Once the card has been downloaded or activated, patients can take it to Walgreens or a participating independent pharmacy to pick up the prescription.
  • Discount pricing is also available for eligible uninsured patients.*

*Terms and conditions apply. Please see full eligibility criteria and terms and conditions at bauschaccessprogram.com.

Message and data rates may apply. Full terms can be viewed at bauschaccess.copaysavingsprogram.com/sms-terms.

FINANCIAL ASSISTANCE FOR THOSE IN NEED

If patients can’t afford BESIVANCE, the Bausch + Lomb Patient Assistance Program may be able to provide medicines at no cost.

  • Applications to the program are reviewed on a case-by-case basis.

‡Terms, conditions and limitations apply. Please see www.bauschhealthpap.com for eligibility rules and terms and conditions.

For more information on the program or to print out an application, click here.

REGISTER FOR UPDATES

Get additional information and resources.

INTERESTED IN BESIVANCE SAMPLES?

Requesting samples is easy.

 
Indication

BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*

*Efficacy for this organism was studied in fewer than 10 infections.

Important Safety Information
  • BESIVANCE is not for injection into the eye.
  • As with other anti-infectives, prolonged use of BESIVANCE may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
  • Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE.
  • The most common adverse event reported in approximately 2% of patients treated with BESIVANCE was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
  • Safety and effectiveness in infants below one year of age have not been established.

Click here for full Prescribing Information for BESIVANCE.

Indication

BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*

*Efficacy for this organism was studied in fewer than 10 infections.

Important Safety Information
  • BESIVANCE is not for injection into the eye.
  • As with other anti-infectives, prolonged use of BESIVANCE may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
  • Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE.
  • The most common adverse event reported in approximately 2% of patients treated with BESIVANCE was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
  • Safety and effectiveness in infants below one year of age have not been established.

Click here for full Prescribing Information for BESIVANCE.

THIS WEBSITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY.

Please choose an option below: